Bispecific antibodies can also be harnessed in the context on engineered T cells as it was recently shown in a study in which CD19 CAR T cells were modified to express an anti-PD1/TGFβ molecule, although this work focused on a hematological cancer model lacking solid tumor TME and did not assess the contribution of the TGFβ blocking moiety alone (44). Here, CD19 is linked to hematopoietic and lymphoid cell neoplasm.